Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
panitumumab + oxaliplatin + levofolinate calcium + fluorouracil
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This drug is a combination chemotherapy regimen consisting of panitumumab, oxaliplatin, levofolinate calcium (L-leucovorin), and fluorouracil (5-FU), typically administered intravenously. Panitumumab is an epidermal growth factor receptor (EGFR) inhibitor and fully human monoclonal antibody used as targeted therapy. Oxaliplatin is a platinum-based alkylating agent that promotes cytotoxicity via DNA crosslinking. Levofolinate calcium (L-leucovorin) is a stabilizer and potentiator of fluorouracil cytotoxicity by enhancing thymidylate synthase inhibition. Fluorouracil is an antimetabolite that inhibits DNA synthesis by blocking thymidylate synthase. This regimen is primarily studied and used in the first-line treatment of advanced or metastatic colorectal cancer with wild-type RAS/BRAF genes[1][2].
- Brand names
- Vectibix
- Other names
- FOLFOX-4 plus panitumumabFOLFOX4 plus panitumumabFOLFOX 4 plus panitumumabVALENTINO regimen
02
Targets
Beyond the preview
Go deeper on panitumumab + oxaliplatin + levofolinate calcium + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on panitumumab + oxaliplatin + levofolinate calcium + fluorouracil.